BILDYOS® (denosumab)
搜索文档
Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025
Businesswire· 2025-11-06 20:30
Nov 6, 2025 7:30 AM Eastern Standard Time Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025 Share JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a primary focus on women's health, will release its third quarter 2025 financial results on November 10, 2025, prior to the company's webcast and conference call scheduled for 8:30 a.m. ET. The webcast and conference call will be hosted by Carrie Cox, Organon's Executive Board Chair ...
European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
Businesswire· 2025-09-19 18:00
公司动态 - 欧洲委员会批准复宏汉霖与Organon的BILDYOS®(地诺单抗)和BILPREVDA®(地诺单抗)生物类似药 [1] 行业进展 - 生物类似药领域监管审批取得新进展 涉及地诺单抗产品 [1]